A phase 2A pilot study to assess the safety and efficacy of eltanexor in relapsed/refractory NPM1-mutated acute myeloid leukemia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514724-16-01

Acronym

ELENA-01

Enrollment

Registered

2025-01-13

Start date

2025-01-14

Completion date

Unknown

Last updated

2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Brief summary

Response rate (sum of CR, CRi, MLFS) by the end of cycle 2, Rate of Grade 5, non-hematological Grade 4 and long-lasting non-hematological Grade 3 adverse events

Interventions

DRUGEltanexor

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Response rate (sum of CR, CRi, MLFS) by the end of cycle 2, Rate of Grade 5, non-hematological Grade 4 and long-lasting non-hematological Grade 3 adverse events	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026